In a recent episode of the SARMs & GLP-1s podcast, hosts Kyle Gillett, MD and James O’Hara, NP dove deep into the increasingly popular—but controversial—use of GLP-1 receptor agonists (like semaglutide) and SARMs (Selective Androgen Receptor Modulators) for body recomposition and aesthetic goals. Here’s a comprehensive breakdown of the key insights.
GLP-1s: From Diabetes Management to Aesthetics
Originally developed to help manage diabetes, GLP-1 receptor agonists such as Ozempic and Wegovy are now being embraced for their cosmetic benefits. Many users seek sharper jawlines, reduced facial puffiness, and quick weight loss.
However, the hosts caution that these drugs come with real risks, including:
- Gastrointestinal issues (nausea, constipation)
- Gallbladder attacks and gastroparesis
- Potential bone density loss and muscle wasting
Even though microdosing might minimize side effects, the long-term risk-benefit ratio may not favor using GLP-1s solely for aesthetics.
SARMs: A Promising Tool for Muscle Preservation?
The discussion shifted to SARMs like Inobosarm (Ostarine), which have resurfaced in interest for their ability to retain lean mass while promoting fat loss. Early trials combining SARMs with GLP-1s in older adults with sarcopenic obesity show promise, especially in terms of improved body composition and reduced muscle loss.
Yet, SARMs’ regulatory status remains murky, and long-term safety data is limited. These compounds might offer a potential “harm reduction” strategy for those already on GLP-1s, but careful consideration and medical supervision are essential.
Bone Health & Experimental Peptides
Bone health emerged as another hot topic. The hosts discussed personal experiments with strontium supplementation and emerging therapies like:
- Amylin analogs (e.g., kagralinotide)
- Calcitonin receptor agonists
These compounds may boost bone density and aid fat loss, though clinical evidence is still emerging. Notably, stacking peptides and GLP-1s is being explored, with the caveat that robust data is lacking and caution is advised.
Critique of Data Transparency & Industry Practices
A major point of criticism was the selective data release and staggered approvals of new therapies. The hosts argue that pharmaceutical companies often prioritize profits over patients, releasing trial data in phases (oral vs. injectable, combination therapies) rather than conducting comprehensive trials upfront.
They also emphasized the importance of more detailed and transparent data—such as waterfall plots and individualized response profiles—to truly assess the benefits and risks of these therapies.
Practical Recommendations & Ethical Practices
Instead of chasing rapid results with experimental medications, the hosts recommend:
– Embracing resistance training and sufficient protein intake
– Being cautious with unregulated peptides and SARMs
– Seeking care from clinics that prioritize transparency and patient well-being
Our clinic, for example, operates on a membership model that avoids profiting from medication markups, offering unbiased care compared to some med spas or “functional” clinics.
